Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr14.60 SEK
Change Today 0.00 / 0.00%
Volume 0.0
MROXA On Other Exchanges
Symbol
Exchange
Stockholm
Stockholm
As of 12:00 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

medirox ab-a shares (MROXA) Snapshot

Open
kr8.55
Previous Close
kr14.60
Day High
kr14.60
Day Low
kr8.55
52 Week High
09/15/14 - kr17.00
52 Week Low
09/1/15 - kr8.55
Market Cap
78.1M
Average Volume 10 Days
484.3
EPS TTM
kr0.50
Shares Outstanding
2.6M
EX-Date
04/24/15
P/E TM
29.3x
Dividend
kr0.25
Dividend Yield
1.82%
Current Stock Chart for MEDIROX AB-A SHARES (MROXA)

Related News

No related news articles were found.

medirox ab-a shares (MROXA) Related Businessweek News

No Related Businessweek News Found

medirox ab-a shares (MROXA) Details

MediRox AB (publ) produces and sells control plasmas and diagnostic reagents for coagulation analytes. It also develops and markets ReoRox rheometers using FOR technology. The company’s coagulation reagents include MRX930 and MRX931 APTT Liquid Reagents for in vitro determination of the activated partial thromboplastin time; AT Antithrombin III LR, a physiological inhibitor of thrombin and factor Xa in plasma, which regulates blood coagulation; D-Dimer, an indicator of thrombotic events, such as deep venous thrombosis, pulmonary embolism, disseminated intravascular coagulation, and pregnancy complications; PT Owren, a lyophilized product based on rabbit thromboplastin and bovine plasma; and PT Quick, an assay to monitor oral anticoagulation therapy, and a fundamental screening test for acquired or inherited bleeding disorders. It also offers coagulation controls comprising Eximius Controls and NKP/OKP Scandinavian Controls; and ReoRox G2, a reagent open system for the evaluation of haemostasis, as well as clot test analysis. The company is based in Nyköping, Sweden.

medirox ab-a shares (MROXA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr986.0K
Compensation as of Fiscal Year 2014.

medirox ab-a shares (MROXA) Key Developments

MediRox AB (publ) to Report First Half, 2015 Results on Aug 24, 2015

MediRox AB (publ) announced that they will report first half, 2015 results on Aug 24, 2015

MediRox AB (publ) to Report Fiscal Year 2014 Results on Feb 23, 2015

MediRox AB (publ) announced that they will report fiscal year 2014 results on Feb 23, 2015

MediRox AB (publ) to Report Q1, 2015 Results on Apr 23, 2015

MediRox AB (publ) announced that they will report Q1, 2015 results on Apr 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MROXA:SS kr14.60 SEK 0.00

MROXA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MROXA.
View Industry Companies
 

Industry Analysis

MROXA

Industry Average

Valuation MROXA Industry Range
Price/Earnings 29.0x
Price/Sales 2.6x
Price/Book 7.5x
Price/Cash Flow 8.4x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIROX AB-A SHARES, please visit www.medirox.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.